Onyx Pharmaceuticals Inc

Entity type image
Type: Company
Name: Onyx Pharmaceuticals Inc
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Negative Session, but Well Off the Lows

(AdviceTrade via COMTEX) --The stock market indices had a very interesting day today and ended lower, but it could have been a lot worse.The day started out with big gaps down as foreign markets were sharply lower. The indices gapped lower and reached ... [Published TradingCharts.com - 1 hour ago]
Entities: Stocks, Comtex, NASDAQ 100
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Onyx Pharmaceuticals Makes a Move: Up 3.7%

(Financial News Network On) Onyx Pharmaceuticals (NASDAQ:ONXX) is a company whose shares are active, trading 3.7% higher to $96.44. The Dow Jones Industrial Average is now trading fractionally lower to 15,304 and the S&P is trading 0.3% lower to 1,650. ... [Published Individual.com - 6 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Potential Onyx Pharmaceuticals (ONXX) Trade Has $87.93 Breakeven

Onyx Pharmaceuticals (NASDAQ: ONXX) closed Wednesday's trading session at $93.03. In the past year, the stock has hit a 52-week low of $41.26 and 52-week high of $101.57. Onyx Pharmaceuticals (ONXX) stock has been showing support around $90.05 and resistance ... [Published MarketIntelligenceCenter.com - 11 hours ago]
First reported May 21 2013 - Updated May 21 2013 - 1 reports

Negative Day, but Strong Technicals

The stock market indices started the week out with upward movement until midsession when the S&P 500 reached just under 1673, a new all-time high, and the Nasdaq 100 reached almost 33. They came down hard in a 5-wave decline, bounced in the afternoon, ... [Published Zecco - May 21 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports

Onyx Pharmaceuticals Price Target Raised to $115.00 at Brean Murray (ONXX)

Equities researchers at Brean Murray lifted their target price on shares of Onyx Pharmaceuticals (NASDAQ: ONXX)Shares of Onyx Pharmaceuticals (NASDAQ: ONXX) traded up 1.14% during mid-day trading on Monday, hitting $96.74. Onyx Pharmaceuticals has a 52 ... [Published American Banking News - Stock Ratings - May 20 2013]
First reported May 20 2013 - Updated May 20 2013 - 1 reports

Onyx Pharmaceuticals Earnings Review: 13 Days after Announcement Shares Up 5.6% (ONXX)

When Onyx Pharmaceuticals (NASDAQ:ONXX) reported earnings 13 days ago on May 7th, 2013, analysts, on average, expected the company to report a loss of $0.48 on sales of $134.3 million. The company actually reported a loss of $0.19 per share on sales of ... [Published Comtex SmarTrend - May 20 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports

Onyx Pharmaceuticals (ONXX) Showing Bullish Technicals But Could Break Through $101.45 Resistance

Onyx Pharmaceuticals (NASDAQ: ONXX) closed Thursday's trading session at $95.35. In the past year, the stock has hit a 52-week low of $41.26 and 52-week high of $101.57. Onyx Pharmaceuticals (ONXX) stock has been showing support around $90.87 and resistance ... [Published TradingCharts.com - May 17 2013]
First reported May 17 2013 - Updated May 17 2013 - 1 reports

Form 4 ONYX PHARMACEUTICALS For: May 14 Filed by: Lasowski Juergen

StreetInsider.com - Form 4 ONYX PHARMACEUTICALS For: May 14 Filed by: Lasowski Juergen ... [Published Street Insider - May 17 2013]
First reported May 16 2013 - Updated May 16 2013 - 1 reports

Negative Day with Poor Close

The stock market indices had a tough session with a late sell-off, putting them into negative territory. The day started out positive as the Nasdaq 100 reached 3019 today, only to rollover and close under 3000 at 2999, 20 points off its high, finishing ... [Published Zecco - May 16 2013]
First reported May 08 2013 - Updated May 09 2013 - 2 reports

Onyx Pharmaceuticals PT Raised to $110.00 (ONXX)

Analysts at UBS AG upped their price target on shares of Onyx Pharmaceuticals (NASDAQ: ONXX)ONXX has been the subject of a number of other recent research reports. Analysts at Leerink Swann raised their price target on shares of Onyx Pharmaceuticals from ... [Published American Banking News - May 09 2013]
First reported May 08 2013 - Updated May 08 2013 - 2 reports

Onyx Pharma Q1 Loss Narrows

WASHINGTON (dpa-AFX) - Onyx Pharmaceuticals, Inc. (ONXX) Tuesday said first-quarter loss narrowed to $33.67 million or $0.47 per share from $56.21 million or $0.88 per share in the same period last year.Adjusted loss for the quarter was $13.7 million ... [Published FinanzNachrichten.de - May 08 2013]
First reported May 07 2013 - Updated May 08 2013 - 3 reports

Onyx Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript

5:00 PM ETOperatorWelcome to the Onyx Pharmaceuticals First Quarter 2013 Conference Call. My name is Ellen, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.I will now turn the call ... [Published Seeking Alpha - May 08 2013]

Quotes

...their patients," said Charles A Simonton, M D , FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "XIENCE Xpedition 48 provides a new, unique solution for treating patients with very long lesions, affirming Abbott's commitment to continued innovation."
CytRx Offers Initial Results from Aldoxorubicin Trial; Abbott Announces CE Mark for World's Longe ... [Published BioMedReports - May 22 2013]
"Despite the availability and advantages of several approved PAH therapies, the prognosis for patients remains poor and mortality remains high. The interim results of PATENT-2 support the benefits of riociguat that were seen in the PATENT-1 trial. We are confident that, together, these results reinforce the role of riociguat, if approved, as a new treatment in the armamentarium against PAH" said Kemal Malik, head of global development at Bayer
Bayer bolsters campaign for PAH drug riociguat with positive long-term data [Published FierceBiotech - May 21 2013]
...settings," said Pablo Cagnoni, M D , Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals. "We are committed to exploring therapies in difficult-to-treat cancers for patients who have limited treatment options."
ONYX PHARMACEUTICALS, INC.: Onyx Pharmaceuticals Announces Data Presentations at 49th American So ... [Published 4 Traders - May 15 2013]
"I think if the trial had been conducted in a better way we would not be here" she said
FDA panel votes against Aveo's kidney cancer drug [Published GlobalPost - May 15 2013]

More Content

All (288) | News (170) | Reports (14) | Blogs (59) | Audio/Video (5) | Fact Sheets (0) | Press Releases (40)
sort by: Date | Relevance
Negative Session, but Well Off the Lows [Published TradingCharts.com - 1 hour ago]
Aveo says partner Astellas will not seek EU nod... [Published Reuters - 1 hour ago]
Onyx Pharmaceuticals Makes a Move: Up 3.7% [Published Individual.com - 6 hours ago]
Ligand to Present at Upcoming Investor Conferences [Published Reuters - 10 hours ago]
LIGAND PHARMACEUTICALS INC. : Ligand to Present... [Published 4 Traders - 11 hours ago]
Potential Onyx Pharmaceuticals (ONXX) Trade Has... [Published MarketIntelligenceCenter.com - 11 hours ago]
Onyx Pharmaceuticals, Inc. Presents at UBS Glob... [Published Seeking Alpha - May 22 2013]
CytRx Offers Initial Results from Aldoxorubicin... [Published BioMedReports - May 22 2013]
Onyx Pharmaceuticals Announces Data Presentatio... [Published Marketwire - Breaking News Releases - May 21 2013]
Bayer bolsters campaign for PAH drug riociguat ... [Published FierceBiotech - May 21 2013]
Negative Day, but Strong Technicals [Published Zecco - May 21 2013]
Onyx Pharmaceuticals Price Target Raised to $11... [Published American Banking News - Stock Ratings - May 20 2013]
Onyx Pharmaceuticals Earnings Review: 13 Days a... [Published Comtex SmarTrend - May 20 2013]
Will ASCO Unlock Big Value in This Cancer Drug ... [Published Motley Fool Discussion Boards - May 18 2013]
Will ASCO Unlock Big Value in This Cancer Drug ... [Published EquityJungle - v0.1 - May 18 2013]
Onyx Pharmaceuticals (ONXX) Showing Bullish Tec... [Published TradingCharts.com - May 17 2013]
Onyx Pharmaceuticals (ONXX) Showing Bullish Tec... [Published MarketIntelligenceCenter.com - May 17 2013]
Form 4 ONYX PHARMACEUTICALS For: May 14 Filed b... [Published Street Insider - May 17 2013]
Negative Day with Poor Close [Published Zecco - May 16 2013]
Who's who in Big Pharma offers appetizing look ... [Published FiercePharma - May 16 2013]
StockCall Early Morning Insight into SQNM, PPHM... [Published Individual.com - May 16 2013]
Top New Biotech Ideas from PropThink [Published 24/7 Wall St - May 16 2013]
Gilead Offers Response Data from Idelalisib; Sa... [Published BioMedReports - May 16 2013]
Form 4 ONYX PHARMACEUTICALS For: May 13 Filed b... [Published Street Insider - May 16 2013]
Form 4 ONYX PHARMACEUTICALS For: May 13 Filed b... [Published Street Insider - May 16 2013]
ONYX PHARMACEUTICALS, INC.: Onyx Pharmaceutical... [Published 4 Traders - May 15 2013]
Onyx Pharmaceuticals Announces Data Presentatio... [Published Marketwire - Breaking News Releases - May 15 2013]
FDA panel votes against Aveo's kidney cancer drug [Published GlobalPost - May 15 2013]
FDA OKs pinpoint prostate cancer radiation drug... [Published FierceBiotech - May 15 2013]
Deutsche Bank Firm on Biotech Stocks to Buy [Published 24/7 Wall St - May 15 2013]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
Anthony Coles, Paul Goddard, William Meyers, [more]
  •  
AVEO Pharmaceuticals Inc, JPMorgan Chase & Co, Bayer AG, [more]
  •  
FDA Food & Drug Administration, American Society of Clinical Oncology, European Hematology Association, [more]
  •  
8-k, Stocks, Healthcare Conference, [more]
  •  
Kyprolis, Nexavar, Stivarga, [more]
  •  
San Francisco (United States), Chicago, Paris, [more]
  •  
United States, Japan, Peru, [more]
  •  
Medicine, Biotechnology, Biology, [more]
  •  
Pharma & Biotech, Health, Banking & Financial Services, [more]
MarketIntelligenceCenter.com, Marketwire - Breaking News Releases, Street Insider, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Potential Onyx Pharmaceuticals (ONXX) Trade Has... [Published MarketIntelligenceCenter.com - 11 hours ago]
Onyx Pharmaceuticals (NASDAQ: ONXX) closed Wednesday's trading session at $93.03. In the past year, the stock has hit a 52-week low of $41.26 and 52-week high of $101.57. Onyx Pharmaceuticals (ONXX) stock has been showing support around $90.05 and resistance ...
Will ASCO Unlock Big Value in This Cancer Drug ... [Published EquityJungle - v0.1 - May 18 2013]
Filed under: Investing There's little denying that Roche 's cancer wonder drug Avastin has been a godsend to cancer patients and investors alike. Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer ...
Onyx Pharmaceuticals (ONXX) Showing Bullish Tec... [Published MarketIntelligenceCenter.com - May 17 2013]
Onyx Pharmaceuticals (NASDAQ: ONXX) closed Thursday's trading session at $95.35. In the past year, the stock has hit a 52-week low of $41.26 and 52-week high of $101.57. Onyx Pharmaceuticals (ONXX) stock has been showing support around $90.87 and resistance ...
Onyx Pharmaceuticals (ONXX) Trading Near $98.99... [Published MarketIntelligenceCenter.com - May 13 2013]
Onyx Pharmaceuticals (NASDAQ: ONXX) closed Friday's trading session at $97.22. In the past year, the stock has hit a 52-week low of $41.26 and 52-week high of $101.57. Onyx Pharmaceuticals (ONXX) stock has been showing support around $94.23 and resistance ...
These 5 Stocks Saw Trading Price Swings This Pa... [Published Wall St. Cheat Sheet - May 12 2013]
Cross Country Healthcare, Inc. ( NASDAQ:CCRN ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.01 in the quarter versus EPS of $0.00 in the year-earlier ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
The Next Big Thing In Biotech: Onyx [Published TheStreet.com - YouTube - Mar 07 2013]
Fireside Chat with N. Anthony Coles, MD, Chairm... [Published BIO Channel - YouTube - Feb 27 2013]
N. Anthony Coles, MD, Chairman & CEO, Onyx Phar... [Published BIO Channel - YouTube - Feb 26 2013]
Fireside Chat with N. Anthony Coles, MD, Chairm... [Published BIO Channel - YouTube - Feb 20 2013]
Wallstrip - Onyx Pharmaceuticals, Inc. (ONXX) [Published Mefeedia Video Tag : canc - Dec 04 2007]
1

Press Releases

sort by: Date | Relevance
Onyx Pharmaceuticals Announces Data Presentatio... [Published Marketwire - Breaking News Releases - May 21 2013]
Onyx Pharmaceuticals Announces Data Presentatio... [Published Marketwire - Breaking News Releases - May 15 2013]
Onyx Pharmaceuticals to Present at Upcoming Inv... [Published Marketwire - Breaking News Releases - May 08 2013]
Onyx Pharmaceuticals Reports First Quarter 2013... [Published Marketwire - Breaking News Releases - May 07 2013]
Research and Markets: Refractory Multiple Myelo... [Published Business Wire - Apr 18 2013]
1 2 3 4 5 6 7 8
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.